Key result
CAR-binding ablated adenoviral vectors dramatically reduce liver transduction and subsequent toxicity in mice.
Why the study?
The nonspecific tissue distribution and associated toxicity of adenoviral vectors limit the full potential of in vivo gene transfer therapy.
Ablating CAR binding in adenoviral vectors reduces liver tropism and systemic toxicity, potentially improving the safety and efficacy of in vivo gene therapy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for safer adenoviral gene therapy vectors; clinical translation untested in humans.
Kim et al. (2006) studied Adenovirus vector toxicity and tropism. CAR-binding ablated adenoviral vectors (dl-K420A-Z and YKLK420A) vs. Cognate control vectors (dl-LacZ and YKL-1) was evaluated on In vivo transduction efficiency and toxicity (serum transaminases, lethality, hepatopathology). CAR-binding ablated adenoviral vectors demonstrated dramatically reduced in vivo transduction in the liver, resulting in substantially diminished general toxicity and lethality in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: